The American Journal of Managed Care16h
Nipocalimab’s Promising Potential in Advancing gMG Care
For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety and efficacy profile of nipocalimab for generalized myasthenia gravis (gMG).
STAT6d
Previewing Immunovant’s myasthenia gravis study readout — with all its quirky nuance
It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.
The American Journal of Managed Care5d
Phase 3 Data Support Nipocalimab for Myasthenia Gravis
The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...
Immunovant price target lowered to $38 from $45 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on Immunovant (IMVT) to $38 from $45 and keeps a Buy rating on the shares. The firm ...
Country music star has made dramatic turnaround after nearly dying in 2024
Colt Ford’s comeback from his heart attack following a show last April in Arizona has been nothing short of remarkable. The ...
pharmaphorum4d
Sanofi drops BTK drug tolebrutinib in myasthenia gravis
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.
Taste of Country6d
Colt Ford Says He’s Lost 60 Pounds Since His Heart Attack
Colt Ford says his near-fatal heart attack last April helped kickstart a weight loss journey that's now trimmed him down by ...